Ningzi Zang
Biographic Data
| ID | 7258233 |
|---|---|
| NAME | Ningzi Zang |
| GIVEN NAMES | Ningzi |
| FAMILY NAME | Zang |
| SIGNATURE | ZANG N |
| AFFILIATIONS | Liaoning University of Traditional Chinese Medicine |
| VERIFIED | No |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 3 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2027 |
| H-INDEX | 0 |
Clinical evidence mapping for 54 types of oral Chinese patent medicines used in adult bronchial asthma
ETHNOPHARMACOLOGICAL RELEVANCE: Oral Chinese patent medicines (CPMs), derived from traditional Chinese medicine (TCM), are commonly utilized in China for adult bronchial asthma (BA); however, the scope and quality of clinical evidence supporting their efficacy remain unclear. AIM OF THE REVIEW: To construct an evidence map of clinical research on 54 oral CPMs for adult BA, focusing on their use as add-on therapy with partial monotherapy evidence …
Evidence map analysis of clinical studies on 42 commonly used oral Chinese patent medicines for the treatment of stable chronic obstructive pulmonary disease
This study rigorously and comprehensively evaluated the clinical evidence of Chinese patent medicines (CPMs) in treating the stable phase of chronic obstructive pulmonary disease (COPD), highlighting problems and solutions. This study aimed to systematically evaluate the clinical evidence of 42 oral CPMs for the treatment of stable COPD using evidence mapping, identifying research trends, methodological quality, and gaps in the current literature…
The mechanism of Shenlong Jianji treatment of idiopathic pulmonary fibrosis inhibits fibroblast-to-myofibroblast transformation via the TGF-β1/smads signaling pathway
No prominent works on this page.
The mechanism of Shenlong Jianji treatment of idiopathic pulmonary fibrosis inhibits fibroblast-to-myofibroblast transformation via the TGF-β1/smads signaling pathway
Evidence map analysis of clinical studies on 42 commonly used oral Chinese patent medicines for the treatment of stable chronic obstructive pulmonary disease
This study rigorously and comprehensively evaluated the clinical evidence of Chinese patent medicines (CPMs) in treating the stable phase of chronic obstructive pulmonary disease (COPD), highlighting problems and solutions. This study aimed to systematically evaluate the clinical evidence of 42 oral CPMs for the treatment of stable COPD using evidence mapping, identifying research trends, methodological quality, and gaps in the current literature…
Clinical evidence mapping for 54 types of oral Chinese patent medicines used in adult bronchial asthma
ETHNOPHARMACOLOGICAL RELEVANCE: Oral Chinese patent medicines (CPMs), derived from traditional Chinese medicine (TCM), are commonly utilized in China for adult bronchial asthma (BA); however, the scope and quality of clinical evidence supporting their efficacy remain unclear. AIM OF THE REVIEW: To construct an evidence map of clinical research on 54 oral CPMs for adult BA, focusing on their use as add-on therapy with partial monotherapy evidence …
Alternative medicine (2 works) · Chinese patent medicine (2 works) · MEDLINE (2 works) · Respiratory and Cough-Related Research (2 works) · Asthma and respiratory diseases (1 works) · Biology (1 works) · Chronic Obstructive Pulmonary Disease (COPD) Research (1 works) · Clinical trial (1 works) · Delphi Technique in Research (1 works) · Disease (1 works)